trial · primary record
Pembrolizumab
Gastroesophageal Junction (GEJ) Adenocarcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 26 |
| Primary completion | 2031-06 |
| Primary endpoint | 3-year event-free survival (EFS) rate |
| Registry ID | NCT07018570 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:51.704Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07018570
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pembrolizumab · approval
- Pembrolizumab · compound